<DOC>
	<DOCNO>NCT02802228</DOCNO>
	<brief_summary>This placebo-controlled study ass safety efficacy 90-day course treatment ifetroban portal hypertension cirrhotic patient</brief_summary>
	<brief_title>Study Assess Safety Efficacy Ifetroban Treatment Portal Hypertension Cirrhotic Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Ifetroban</mesh_term>
	<criteria>liver cirrhosis baseline HVPG &gt; = 8 mmHg &lt; = 16 mmHg stable liver function enzymes portal splenic vein thrombosis TIPS portocaval shunt variceal bleed last 2 month hemodialysis ChildPugh Score &gt; = 12 MELDNa &gt; = 20 Acute kidney injury , Chronic kidney disease and/or Serum Creatinine &gt; = 2.0 mg/dL current alcohol consumption &gt; 2 drink per day PLT &lt; 80 x 10^3/uL A change statin therapy last 3 month Current HBV HCV therapy ; plan initiation therapy treatment period Myocardial infarction within 30 day History bleed diathesis current ( within previous 14 day ) plan use anticoagulant antiplatelet drug include aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>